Weight gain, smoking cessation, and cardiovascular risk

It is known that smoking cessation substantially reduces the risk of cardiovascular disease (CVD), but does any subsequent weight gain attenuate the benefits of quitting smoking? ┬áThe goal of this study was to answer this question in adults with and without diabetes. ┬áSpecifically, the authors tested the hypothesis that quitting smoking decreases CVD risk compared […]

Read More…

Varenicline: no link with cardiovascular events found in meta-analysis

Varenicline (Champix) is a partial agonist to nicotine receptors, and is approved for smoking cessation therapy. However, the FDA has raised concern about a possible increase in the incidence of cardiovascular events of patients taking the drug in randomised trials. In this meta-analysis, Prochaska et al. looked at 22 randomised controlled trials of current tobacco […]

Read More…